Around 2,400 people in England have ES-SCLC, of whom around 1,200 people will be eligible to receive Tecentriq plus carboplatin and etoposide. NICE noted that clinical trial evidence suggests ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback